Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
Table 4
Laboratory abnormalities at baseline before switching and after treatment.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Laboratory abnormalities at baseline before switching and after treatment.